Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 118


The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.

Rasmussen SA, Rosebush PI, Anglin RE, Mazurek MF.

Psychiatry Res. 2016 Jul 30;241:72-7. doi: 10.1016/j.psychres.2016.04.097. Epub 2016 Apr 29.


Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials.

Fornaro M, Stubbs B, De Berardis D, Perna G, Valchera A, Veronese N, Solmi M, Ganança L.

Int J Mol Sci. 2016 Feb 16;17(2):241. doi: 10.3390/ijms17020241.


Asenapine for bipolar disorder.

Scheidemantel T, Korobkova I, Rej S, Sajatovic M.

Neuropsychiatr Dis Treat. 2015 Dec 4;11:3007-17. doi: 10.2147/NDT.S78043. eCollection 2015. Review.


Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder.

Kim SW, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald PB, Kim JM, Yoon JS, Berk M.

Psychiatry Investig. 2015 Jul;12(3):349-55. doi: 10.4306/pi.2015.12.3.349. Epub 2015 Jul 6.


Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group.

Xu L, Lu Y, Yang Y, Zheng Y, Chen F, Lin Z.

Neuropsychiatr Dis Treat. 2015 May 25;11:1265-71. doi: 10.2147/NDT.S81146. eCollection 2015.


Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial.

Detke HC, DelBello MP, Landry J, Usher RW.

J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):217-24. doi: 10.1016/j.jaac.2014.12.012. Epub 2014 Dec 29.


Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.

Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E.

J Clin Psychiatry. 2015 Jun;76(6):728-34. doi: 10.4088/JCP.13m08827.


Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial.

Mostafavi A, Solhi M, Mohammadi MR, Hamedi M, Keshavarzi M, Akhondzadeh S.

Acta Med Iran. 2014;52(10):734-9.


The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: trauma and early psychotic mania.

Daglas R, Conus P, Cotton SM, Macneil CA, Hasty MK, Kader L, Berk M, Hallam KT.

Aust N Z J Psychiatry. 2014 Nov;48(11):1017-24. doi: 10.1177/0004867414545672. Epub 2014 Aug 13.


The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.

Smith LT, Shelton CL, Berk M, Hasty MK, Cotton SM, Henry L, Daglas R, Gentle E, McGorry PD, Macneil CA, Conus P.

J Affect Disord. 2014;167:74-9. doi: 10.1016/j.jad.2014.05.055. Epub 2014 Jun 2.


Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder.

Kim SW, Berk L, Kulkarni J, Dodd S, de Castella A, Fitzgerald PB, Amminger GP, Berk M.

J Affect Disord. 2014 Sep;166:243-8. doi: 10.1016/j.jad.2014.05.017. Epub 2014 May 23.


Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.

Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H.

J Affect Disord. 2014 Aug;164:57-62. doi: 10.1016/j.jad.2014.04.003. Epub 2014 Apr 16.


Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.

Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, Hansen K.

J Med Econ. 2014 Jul;17(7):508-19. doi: 10.3111/13696998.2014.914030. Epub 2014 Apr 30.


Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study.

Wang M, Tong JH, Huang DS, Zhu G, Liang GM, Du H.

Psychopharmacology (Berl). 2014 Jul;231(14):2811-8. doi: 10.1007/s00213-014-3453-1. Epub 2014 Jan 31.


A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life.

Strzelecki D, Tabaszewska A, Barszcz Z, Józefowicz O, Kropiwnicki P, Rabe-Jabłońska J.

Psychiatry Investig. 2013 Dec;10(4):421-4. doi: 10.4306/pi.2013.10.4.421. Epub 2013 Dec 16.


Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.

Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC.

Psychiatry Clin Neurosci. 2014 Jul;68(7):498-505. doi: 10.1111/pcn.12156. Epub 2014 Mar 4.


Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.

Uttley L, Kearns B, Ren S, Stevenson M.

Pharmacoeconomics. 2013 Nov;31(11):981-90. doi: 10.1007/s40273-013-0091-0. Review.


The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.

Lee HB, Yoon BH, Kwon YJ, Woo YS, Lee JG, Kim MD, Bahk WM.

Clin Drug Investig. 2013 Oct;33(10):743-53. doi: 10.1007/s40261-013-0120-y. Review.


[Olanzapine in manic/mixed patients with or without substance abuse].

Sani G, Simonetti A, Serra G, Solfanelli A, Girardi N, Janiri D, Danese E, Rapinesi C, Tatarelli R, Girardi P.

Riv Psichiatr. 2013 Mar-Apr;48(2):140-5. doi: 10.1708/1272.14038. Italian.


Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.

Vita A, De Peri L, Siracusano A, Sacchetti E; ATOM group.

Int Clin Psychopharmacol. 2013 Sep;28(5):219-27. doi: 10.1097/YIC.0b013e32836290d2.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk